Treatment guidance for prostate cancer patients is not optimal because current clinical tests do not clearly differentiate between slow-growing and aggressive forms. An EU-funded project is addressing this by studying the underlying molecular mechanisms of the disease to enable personalised and effective treatment.from EUROPA - Syndicated Research News Feed https://ift.tt/2ynW6vN
via IFTTT
No comments:
Post a Comment